2.3 Viruses. Clinical isolates of HSV-1 and HSV-2 were kindly provided by Prof. M. Pistello, 103
2 ABSTRACT 25 ETHNOPHARMACOLOGICAL RELEVANCE: Shilajit, a herbomineral substance exuded from 26 rocks in steep mountainous regions, has been used for thousands of years by the Indian Ayurvedic 27
and Siddha systems of traditional medicine to relieve ailments and enhance quality of life. Although 28 a large number of therapeutic properties have been ascribed to Shilajit, its therapeutic potential is 29 still largely unexplored by modern research and many of its claimed bioactivities lack scientific 30
validation. The present study was undertaken to investigate the antiviral activity of Shilajit against a 31 panel of viruses including herpes simplex type 1 and 2 (HSV-1, HSV-2), human cytomegalovirus 32 (HCMV), human respiratory syncytial virus (RSV), human rotavirus (HRV), and vesicular 33 stomatitis virus (VSV). 34
MATERIALS AND METHODS: The antiviral activity of Shilajit was assayed in vitro by plaque 35
reduction and virus yield assays and the major mechanism of action was investigated by virucidal 36 and time-of-addition assays. 37 RESULTS: Shilajit exhibited a dose-dependent inhibitory activity against HSV1, HSV2, HCMV, 38
and RSV infectivity in vitro (EC 50 values: 31.08 g/ml, 12.85 g/ml, 34.54 g/ml, and 30.35 g/ml, 39 respectively), but was inactive against HRV and VSV. Humic acid, a constituent of Shilajit, 40 displayed the same spectrum of activity. Partial virus inactivation and interference with virus 41 attachment were both found to contribute to the antiviral activity of Shilajit. 42
CONCLUSIONS:
The results of the present study demonstrate that Shilajit is endowed with broad, 43 yet specific, antiviral activity in vitro and constitutes a natural source of antiviral substances. 44
Further work remains to be done to assess its efficacy in vivo. 45 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 4 antiviral potential of Shilajit has yet to be explored, with only its anti-HIV action having received 73 research attention to date (Ghosal, 2006 , Gupta et al., 2010 , Rege et al., 2012 . The antiviral activity 74 of one of its components, humic acid has been partially explored (Klöcking et al., 2005) . 75
The present study was undertaken to investigate the antiviral activity of Shilajit against a panel of 76 viruses, consisting of herpes simplex types 1 and 2 (HSV-1, HSV-2), human cytomegalovirus 77 (HCMV), human respiratory syncytial virus (RSV), human rotavirus (HRV), and vesicular 78 stomatitis virus (VSV); these viruses were selected as they encompass a range of viral 79 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 7 20% ethanol and viral plaques counted. The effective concentration producing 50% reduction in 135 plaque formation (EC 50 ) was determined using Prism software by comparing drug-treated with 136 untreated wells. The selectivity index (SI) was calculated by dividing the CC 50 by the EC 50 value. 137 2.6 HCMV inhibition assay. HELF cells were pre-plated in a 96-well plate. The following day 138 serial dilutions of Shilajit or humic acid were added to cells and incubated for 2 h at 37°C. Virus 139 (MOI 0.005) and compound were then added and the cells incubated for a further 2 h; monolayers 140
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RESULTS AND DISCUSSION. 208
To test whether Shilajit can affect HSV-1, HSV-2, HCMV, RSV, human rotavirus, and VSV 209 infectivity in vitro, we used a complete protection assay in which the compound was added to the 210 cell culture before, during, and after the infection. Shilajit exhibited dose-dependent inhibitory 211 activity against HSV1, HSV2, HCMV, and RSV infectivity; the EC 50 values are shown in Table 1 
HSV-1, HSV-2, and HCMV) and one of the Paramyxoviridae family (RSV), the lack of inhibitory 217 activity against rotavirus (Reoviridae) and VSV (Rhabdoviridae) indicates that the spectrum of 218
Shilajit's activity is specific to definite viruses. 219 220 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 To investigate Shilajit's mechanism of action we performed a series of time-of-addition assays, in 237 which the compound was added to the cells only before, or during, or after infection. As shown in 238 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 further experiments as representative viruses of the Herpesviridae and Paramyxoviridae virus 253 families, respectively. First, we carried out an attachment assay, an experimental condition in which 254 the virus is allowed to bind to the surface of the host cells, in the presence or absence of Shilajit, but 255 not undergo cell entry. As shown in Fig. 2A , Shilajit inhibited HSV-2 and RSV infectivity with 256 EC 50 of 14.20 g/ml and 25.70 g/ml, respectively; values that are comparable to those reported in 257 Table 1 . This result indicates that the antiviral activity of Shilajit depends, at least in part, on its 258 capacity to prevent the attachment of the viruses to the cell surface. By contrast, when the antiviral 259 activity of Shilajit was tested using an entry assay in which Shilajit was added immediately after 260 virus attachment to assess its ability to prevent entry, only a weak inhibition was observed at high 261 doses (Fig. 2B) . 
272
To explore the possibility that Shilajit also exerts direct virus-inactivating activity, a virucidal assay 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 (EC 90 ) in the standard assay. To this end, HSV-2 and RSV aliquots were incubated with 100 g/ml 275 Shilajit at 4°C or 37°C for 2 h. After incubation, the samples were titrated on Vero or A549 cells 276 using high dilutions at which Shilajit was no longer active as an antiviral. When the incubations 277
were carried out at 37°C, Shilajit produced a significant loss of both HSV-2 (71.2% inhibition) and 278 RSV (74.4% inhibition) titers, although the treatment did not completely abrogate infectivity. This 279 result indicates that partial virus inactivation contributes to the overall antiviral activity of Shilajit. 280
By contrast, no virucidal activity was observed when the incubation was carried out at 4°C. This 281 latter result rules out the possibility that the antiviral activity observed in the attachment assay, 282 performed at 4°C, was due to a direct virus inactivation. To complete the in vitro analysis of the antiviral potential of Shilajit against HSV-2 and RSV, the 296 compound was also evaluated by viral yield reduction assay -a more stringent test which allows 297 multiple cycles of viral replication to occur before measuring the production of infectious viruses. 298
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322
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